Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps, rubella and varicella virus vaccine live + pneumococcal 7-valent conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
This combination refers to the concurrent administration of the live-attenuated measles, mumps, rubella, and varicella (MMRV) vaccine and the 7-valent pneumococcal conjugate vaccine (PCV7). The MMRV component (such as ProQuad or Priorix-Tetra) provides immunity against four viral pathogens, while the PCV7 component (Prevnar) protects against invasive diseases caused by seven serotypes of Streptococcus pneumoniae. This regimen is a standard part of pediatric immunization schedules, typically administered to children between 12 and 15 months of age. The combination has been extensively studied to ensure that co-administration does not compromise the immunogenicity or safety profile of either vaccine.
- Brand names
- ProQuadPrevnarPriorix-Tetra
- Other names
- MMRV + PCV7ProQuad + Prevnar
02
Targets
MV (Measles virus)Mumps virus antigenCPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)VZV (Varicella-zoster virus)Streptococcus pneumoniae serotype 19F capsular polysaccharide9V CPS (Streptococcus pneumoniae serotype 9V capsular polysaccharide)
Beyond the preview
Go deeper on measles, mumps, rubella and varicella virus vaccine live + pneumococcal 7-valent conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps, rubella and varicella virus vaccine live + pneumococcal 7-valent conjugate vaccine.